Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Omeros has reported encouraging data from the single-ascending-dose (SAD) study part of Phase 1 trial of OMS824 and advanced the investgational CNS drug candidate into next stage.
Subscribe to our email newsletter
OMS824 was well tolerated in the SAD study in which expected pharmacological effects were established in healthy subjects.
The trial was designed to assess the multiple-dose administration of OMS824, a lead compound in phosphodiesterase 10 (PDE10) program. Complete data is expected in 2013.
Omeros chairman and chief executive officer Gregory Demopulos said the company intends to complete Phase 1 trial and commence studies in schizophrenia patients.
"While preparing for the next set of OMS824 studies, our pipeline continues to advance toward additional near-term milestones – Phase 3 data for OMS103HP this month, an NDA submission next quarter and, for as many as three additional programs, entry into the clinic in 2013," Demopulos added.